Arcutis Biotherapeutics Inc (ARQT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcutis Biotherapeutics Inc (ARQT) has a cash flow conversion efficiency ratio of 0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.24 Million) by net assets ($189.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Arcutis Biotherapeutics Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Arcutis Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Arcutis Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arcutis Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcutis Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marriot Vacations Worldwide
NYSE:VAC
|
-0.002x |
|
Exxaro Resources Ltd
JSE:EXX
|
0.081x |
|
Qingdao Huicheng Environmental Co Ltd
SHE:300779
|
-0.010x |
|
Shenzhen Jame Technology Corp Ltd
SHE:300868
|
0.013x |
|
Acer Incorporated
F:AC5G
|
0.017x |
|
Hand Enterprise Solutions Co
SHE:300170
|
-0.011x |
|
Neptune Insurance Holdings Inc.
NYSE:NP
|
-0.056x |
|
Shenzhen Xinyichang Technology Co. Ltd. A
SHG:688383
|
0.019x |
Annual Cash Flow Conversion Efficiency for Arcutis Biotherapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Arcutis Biotherapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Arcutis Biotherapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $189.48 Million | $-5.62 Million | -0.030x | +95.83% |
| 2024-12-31 | $157.54 Million | $-112.16 Million | -0.712x | +74.45% |
| 2023-12-31 | $88.67 Million | $-247.06 Million | -2.786x | -126.59% |
| 2022-12-31 | $209.58 Million | $-257.71 Million | -1.230x | -109.61% |
| 2021-12-31 | $297.68 Million | $-174.63 Million | -0.587x | -40.45% |
| 2020-12-31 | $270.62 Million | $-113.03 Million | -0.418x | +1.07% |
| 2019-12-31 | $101.46 Million | $-42.84 Million | -0.422x | -171.90% |
| 2018-12-31 | $-23.99 Million | $-14.09 Million | 0.587x | -22.33% |
| 2017-12-31 | $-4.99 Million | $-3.77 Million | 0.756x | -- |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more